Shabani et al., Pulmonary Pharmacology & Therapeutics,
doi:10.1016/j.pupt.2021.102069 (Peer Reviewed)
Evaluation of the Prophylactic Effect of Hydroxychloroquine on People in Close-Contact with Patients with Covid-19
Small PEP trial with 51 HCQ patients, not showing a significant difference in cases. IRCT20130917014693N10.
Shabani et al., 8/10/2021, prospective, Iran, Middle East, peer-reviewed, 16 authors.
risk of symptomatic case, 19.0% lower, RR 0.81, p = 1.00, treatment 2 of 51 (3.9%), control 3 of 62 (4.8%), day 7.
risk of COVID-19 case, 6.4% higher, RR 1.06, p = 1.00, treatment 7 of 51 (13.7%), control 8 of 62 (12.9%), day 7, PCR+ and symptomatic.
risk of COVID-19 case, 21.6% higher, RR 1.22, p = 0.78, treatment 7 of 51 (13.7%), control 7 of 62 (11.3%), day 7, PCR+ only.
Effect extraction follows
pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.